Drug Profile
CLX 162
Alternative Names: CLX-162; CLX-OPH-65Latest Information Update: 22 Sep 2022
Price :
$50
*
At a glance
- Originator Cellix Bio
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cataracts
Most Recent Events
- 22 Sep 2022 Cellix Bio pipeline, September 2022- reverted preclinical line in dev table, updated intro KDM, HE
- 28 Mar 2022 No recent reports of development identified for preclinical development in Cataracts in India
- 20 Feb 2018 Preclinical trials in Cataracts in India (unspecified route) (Cellixbio pipeline, February 2018)